COSCIENS Biopharma Current Assets

The latest current assets for AEZS is $33M as of June 2024. That compares with $46M in the prior-year period — down 27.6% year over year. Investors often review this figure alongside COSCIENS Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, AEZS's current assets moved from $46M to $33M — a 27.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in COSCIENS Biopharma's operating scale or balance-sheet position.

A current assets figure of $33M for AEZS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AEZS's current assets ($33M), review year-over-year change from $46M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack COSCIENS Biopharma's current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.